Juno Therapeutics
400 Dexter Avenue North, Suite 1200, Seattle, WA, 98109, United States
Overview
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 9
Sector focus
- Biotechnology
- Clinical Trials
- Health Care
- Medical
- Oncology
- Therapeutics
Investment portfolio
- JW Therapeutics
Participated · Series A · Mar 2018
JW Therapeutics, founded in 2016 by Juno Therapeutics and WuXi AppTec Group, is a Shanghai-based clinical-stage biopharmaceutical company focused on cell-based therapy technologies. The company has initiated development of its first CD19-directed investigational therapy, JWCAR029, a CAR-T being studied for B‑cell malignancies with an initial focus on relapsed and refractory DCBCL. JWCAR029 has moved into clinical phase and its IND was accepted by the China Food and Drug Administration (CFDA). JW Therapeutics has built a fully validated clinical GMP facility aligned with global QMS standards and assembled a leadership team of seasoned biotech/pharma executives led by CEO Hans Bishop. The company completed a $90M Series A financing and will use the proceeds to further advance the JWCAR029 clinical program and develop a broader therapeutic pipeline. JW Therapeutics also plans to build a new commercial manufacturing facility.